The New Bisphosphonate, Zometa^® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate

REFERENCES

• Coleman R.E. Skeletal Complications of Malignancy. Cancer 1997; 80(Suppl.)1588–1594
   PubMed Web of Science ®Google Scholar
• Parkin D.M., Pisani P., Ferlay J. Global Cancer Statistics. CA. Cancer J. Clin. 1999; 49: 33–64
   PubMed Web of Science ®Google Scholar
• Wilson M.A., Calhoun F.W. The Distribution of Skeletal Metastases in Breast and Pulmonary Cancer: Concise Communication. J. Nucl. Med. 1981; 22: 594–597
   PubMed Web of Science ®Google Scholar
• Hortobagyi G.N. Bone Metastases in Breast Cancer Patients. Semin. Oncol. 1991; 18(Suppl. 5)11–15
   PubMedGoogle Scholar
• Jacobs S.C. Spread of Prostatic Cancer to Bone. Urology 1983; 21: 337–344
   PubMed Web of Science ®Google Scholar
• Mundy G.R. Metastatic Bone Disease. Bone Remodeling and Its Disorders. 2nd Ed., Martin Duntiz Ltd., London 1999; 123–146
   Google Scholar
• Berruti A., Dogliotti L., Bitossi R., Fasolis G., Gorzegno G., Bellina M., Torta M., Porpiglia F., Fontana D., Angeli A. Incidence of Skeletal Complications in Patients with Bone Metastatic Prostate Cancer and Hormone Refractory Disease: Predictive Role of Bone Resorption and Formation Markers Evaluated at Baseline. J. Urol. 2000; 164: 1248–1253
   PubMed Web of Science ®Google Scholar
• Body J.J. Bisphosphonates. Eur. J. Cancer 1998; 34: 263–269
   PubMed Web of Science ®Google Scholar
• Mundy G.R. Mechanisms of Bone Metastasis. Cancer 1997; 80: 1546–1556
   PubMed Web of Science ®Google Scholar
• Berruti A., Dogliotti L., Tucci M., Tarabuzzi R., Fontana D., Angeli A. Metabolic Bone Disease Induced by Prostate Cancer: Rationale for the Use of Bisphosphonates. J. Urol. 2001; 166: 2023–2031
   PubMed Web of Science ®Google Scholar
• Marquardt H., Lioubin M.N., Ikeda T. Complete Amino Acid Sequence of Human Transforming Growth Factor Type Beta 2. J. Biol. Chem. 1987; 262: 12127–12131
   PubMed Web of Science ®Google Scholar
• Mayahara H., Ito T., Nagai H., Miyajima H., Tsukuda R., Taketomi S., Mizoguchi J., Kato K. In Vivo Stimulation of Endosteal Bone Formation by Basic Fibroblast Growth Factor in Rats. Growth Factors 1993; 9: 73–80
   PubMed Web of Science ®Google Scholar
• Dunstan C.R., Boyce R., Boyce B.F., Garrett I.R., Izbicka E., Burgess W.H., Mundy G.R. Systemic Administration of Acidic Fibroblast Growth Factor (FGF-1) Prevents Bone Loss and Increases New Bone Formation in Ovariectomized Rats. J. Bone Miner. Res. 1999; 14: 953–959
   PubMed Web of Science ®Google Scholar
• Izbicka E., Dunstan C., Esparza J., Jacobs C., Sabatini M., Mundy G.R. Human Amniotic Tumor That Induces New Bone Formation In Vivo Produces Growth-Regulatory Activity In Vitro for Osteoblasts Identified as an Extended Form of Basic Fibroblast Growth Factor. Cancer Res. 1996; 56: 633–636
   PubMed Web of Science ®Google Scholar
• Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., Gutierrez G. Stimulation of Bone Formation In Vitro and in Rodents by Statins. Science 1999; 286: 1946–1949, [see comments]
   PubMed Web of Science ®Google Scholar
• Cramer S.D., Chen Z., Peehl D.M. Prostate Specific Antigen Cleaves Parathyroid Hormone-Related Protein in the PTH-Like Domain: Inactivation of PTHrP-Stimulated cAMP Accumulation in Mouse Osteoblasts. J. Urol. 1996; 156: 526–531
   PubMed Web of Science ®Google Scholar
• Nelson J.B., Hedican S.P., George D.J., Reddi A.H., Piantadosi S., Eisenberger M.A., Simons J.W. Identification of Endothelin-1 in the Pathophysiology of Metastatic Adenocarcinoma of the Prostate. Nat. Med. 1995; 1: 944–949
   PubMed Web of Science ®Google Scholar
• Clarke N.W., McClure J., George N.J. Morphometric Evidence for Bone Resorption and Replacement in Prostate Cancer. Br. J. Urol. 1991; 68: 74–80
   PubMedGoogle Scholar
• Clarke N.W., McClure J., George N.J. Disodium Pamidronate Identifies Differential Osteoclastic Bone Resorption in Metastatic Prostate Cancer. Br. J. Urol. 1992; 69: 64–70
   PubMedGoogle Scholar
• Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E., Delmas P.D. Markers of Bone Turnover for the Management of Patients with Bone Metastases from Prostate Cancer. Br. J. Cancer 2000; 82: 858–864
   PubMed Web of Science ®Google Scholar
• Percival R.C., Urwin G.H., Harris S., Yates A.J., Williams J.L., Beneton M., Kanis J.A. Biochemical and Histological Evidence That Carcinoma of the Prostate Is Associated with Increased Bone Resorption. Eur. J. Surg. Oncol. 1987; 13: 41–49
   PubMedGoogle Scholar
• Taube T., Kylmala T., Lamberg-Allardt C., Tammela T.L., Elomaa I. The Effect of Clodronate on Bone in Metastatic Prostate Cancer. Histomorphometric Report of a Double-Blind Randomised Placebo-Controlled Study. Eur. J. Cancer 1994; 30A: 751–758
   PubMed Web of Science ®Google Scholar
• Kanis J.A., O'Rourke N., McCloskey E.V. Consequences of Neoplasia Induced Bone Resorption and the Use of Clodronate. Int. J. Oncol. 1994; 5: 713–731
   PubMed Web of Science ®Google Scholar
• Vinholes J., Coleman R., Eastell R. Effects of Bone Metastases on Bone Metabolism: Implications for Diagnosis. Imaging and Assessment of Response to Cancer Treatment. Cancer Treat. Rev. 1996; 22: 289–331
   PubMed Web of Science ®Google Scholar
• Rico H., Uson A., Hernandez E.R., Prados P., Paramo P., Cabranes J.A. Hyperparathyroidism in Metastases of Prostatic Carcinoma: A Biochemical, Hormonal and Histomorphometric Study. Eur. Urol. 1990; 17: 35–39
   PubMed Web of Science ®Google Scholar
• Taube T., Beneton M.N., Williams J.L., McCloskey E.V., Kanis J.A. Distinction Between Focally Accelerated Bone Formation and Osteomalacia in Carcinoma of Prostate Metastasised to Bone. Br. J. Urol. 1993; 72: 98–103
   PubMedGoogle Scholar
• Berruti A., Sperone P., Fasolis G., Torta M., Fontana D., Dogliotti L., Angeli A. Pamidronate Administration Improves the Secondary Hyperparathyroidism Due to “Bone Hunger Syndrome” in a Patient with Osteoblastic Metastases from Prostate Cancer. Prostate 1997; 33: 252–255
   Google Scholar
• Charhon S.A., Chapuy M.C., Delvin E.E., Valentin-Opran A., Edouard C.M., Meunier P.J. Histomorphometric Analysis of Sclerotic Bone Metastases from Prostatic Carcinoma Special Reference to Osteomalacia. Cancer 1983; 51: 918–924
   PubMed Web of Science ®Google Scholar
• Burki F., Coindre J.M., Mauriac L. Sclerotic Bone Metastases of Prostatic Origin and Osteomalacia. Importance of a Histomorphometry Study. Progr. Clin. Biol. Res. 1987; 243A: 569–571
   PubMedGoogle Scholar
• Dodwell, D.J.; Howell, A. In the Systemic Treatment of Bone Metastases. In Bone Metastases: Diagnosis and Treatment; Springer-Verlag: London, 91; 121–147.
   Google Scholar
• Hillner B.E., Ingle J.N., Berenson J.R., Janjan N.A., Albain K.S., Lipton A., Yee G., Biermann J.S., Chlebowski R.T., Pfister D.G. American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer. J. Clin. Oncol. 2000; 18: 1378–1391
   PubMed Web of Science ®Google Scholar
• Hortobagyi G.N., Theriault R.L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler H., Simeone J.F., Seaman J., Knight R.D., Heffernan M., Reistma D.J., Kennedy I., Allan S.G., Mellars K. Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 1996; 335: 1785–1792
   PubMed Web of Science ®Google Scholar
• Hortobagyi G.N., Theriault R.L., Lipton A., Porter L., Blayney D., Sinoff C., Wheeler H., Simeone J.F., Seaman J.J., Knight R.D., Heffernan M., Mellars K., Reitsma D.J. Long-Term Prevention of Skeletal Complications of Metastatic Breast Cancer with Pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J. Clin. Oncol. 1998; 16: 2038–2044
   PubMed Web of Science ®Google Scholar
• Theriault R.L., Lipton A., Hortobagyi G.N., Leff R., Gluck S., Stewart J.F., Costello S., Kennedy I., Simeone J., Seaman J.J., Knight R.D., Mellars K., Heffernan M., Reitsma D.J. Pamidronate Reduces Skeletal Morbidity in Women with Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial. Protocol 18 Aredia Breast Cancer Study Group. J. Clin. Oncol. 1999; 17: 846–854
   PubMed Web of Science ®Google Scholar
• Lipton A., Theriault R.L., Hortobagyi G.N., Simeone J., Knight R.D., Mellars K., Reitsma D.J., Heffernan M., Seaman J.J. Pamidronate Prevents Skeletal Complications and Is Effective Palliative Treatment in Women with Breast Carcinoma and Osteolytic Bone Metastases: Long Term Follow-up of Two Randomized, Placebo-Controlled Trials. Cancer 2000; 88: 1082–1090
   PubMed Web of Science ®Google Scholar
• Cook R.J., Major P. Methodology for Treatment Evaluation in Patients with Cancer Metastatic to Bone. J. Natl Cancer Inst. 2001; 93: 534–538
   PubMed Web of Science ®Google Scholar
• Clarke N.W., Holbrook I.B., McClure J., George N.J. Osteoclast Inhibition by Pamidronate in Metastatic Prostate Cancer: A Preliminary Study. Br. J. Cancer 1991; 63: 420–423
   PubMed Web of Science ®Google Scholar
• Adami S., Salvagno G., Guarrera G., Bianchi G., Dorizzi R., Rosini S., Mobilio G., Lo Cascio V. Dichloromethylene-Diphosphonate in Patients with Prostatic Carcinoma Metastatic to the Skeleton. J. Urol. 1985; 134: 1152–1154
   PubMed Web of Science ®Google Scholar
• Carey P.O., Lippert M.C. Treatment of Painful Prostatic Bone Metastases with Oral Etidronate Disodium. Urology 1988; 32: 403–407
   PubMed Web of Science ®Google Scholar
• Kylmala T., Tammela T.L., Lindholm T.S., Seppanen J. The Effect of Combined Intravenous and Oral Clodronate Treatment on Bone Pain in Patients with Metastatic Prostate Cancer. Ann. Chir. Gynaecol. 1994; 83: 316–319
   PubMedGoogle Scholar
• Cresswell S.M., English P.J., Hall R.R., Roberts J.T., Marsh M.M. Pain Relief and Quality-of-Life Assessment Following Intravenous and Oral Clodronate in Hormone-Escaped Metastatic Prostate Cancer. Br. J. Urol. 1995; 76: 360–365
   PubMedGoogle Scholar
• Adami S. Bisphosphonates in Prostate Carcinoma. Cancer 1997; 80: 1674–1679
   PubMed Web of Science ®Google Scholar
• Pelger R.C., Hamdy N.A., Zwinderman A.H., Lycklama a Nijeholt A.A., Papapoulos S.E. Effects of the Bisphosphonate Olpadronate in Patients with Carcinoma of the Prostate Metastatic to the Skeleton. Bone 1998; 22: 403–408
   PubMed Web of Science ®Google Scholar
• Smith J.A. Palliation of Painful Bone Metastases from Prostate Cancer Using Sodium Etidronate: Results of a Randomized, Prospective, Double-Blind, Placebo-Controlled Study. J. Urol. 1989; 141: 85–87
   PubMed Web of Science ®Google Scholar
• Elomaa I., Kylmala T., Tammela T., Viitanen J., Ottelin J., Ruutu M., Jauhiainen K., Ala-Opas M., Roos L., Seppanen J., et al. Effect of Oral Clodronate on Bone Pain. A Controlled Study in Patients with Metastatic Prostatic Cancer. Int. Urol. Nephrol. 1992; 24: 159–166
   PubMed Web of Science ®Google Scholar
• Strang P., Nilsson S., Brandstedt S., Sehlin J., Borghede G., Varenhorst E., Bandman U., Borck L., Englund G., Selin L. The Analgesic Efficacy of Clodronate Compared with Placebo in Patients with Painful Bone Metastases from Prostatic Cancer. Anticancer Res. 1997; 17: 4717–4721
   PubMed Web of Science ®Google Scholar
• Kylmala T., Taube T., Tammela T.L., Risteli L., Risteli J., Elomaa I. Concomitant i.v. and Oral Clodronate in the Relief of Bone Pain—A Double-Blind Placebo-Controlled Study in Patients with Prostate Cancer. Br. J. Cancer 1997; 76: 939–942
   PubMed Web of Science ®Google Scholar
• Lipton, A.; Small, E.; Saad, F.; Gleason, D.; Gordon, D.; Smith, M.; Rosen, L.; Ortu Kowalski, M.; Reitsma, D.; Seaman, J. The New Bisphosphonate, ZOMETA® (Zoledronic Acid) Decreases Skeletal Complications in Both Lytic and Blastic Lesions: A Comparison to Pamidronate. Chemotherapy Foundation Symposium XIX: Innovative Cancer Therapy for Tomorrow, New York, NY, Nov 7–10, 2001.
   Google Scholar
• Berruti A., Cerutti S., Mari M., Terrone C., Fasolis G., Ardissone P., Reimondo G., Fontana D., Isaia G., Rocca Rossetti S., Dogliotti L., Angeli A. Dual Energy X-Ray Absorptiometry (DEXA) in Detecting Bone Loss During Androgen Deprivation in Prostate Cancer Patients. Proc. Am. Soc. Clin. Oncol. 2000; 19: 333a
   Google Scholar
• Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., Stratte P.T. Progressive Osteoporosis During Androgen Deprivation Therapy for Prostate Cancer. J. Urol. 2000; 163: 181–186
   PubMed Web of Science ®Google Scholar
• Smith M.R., McGovern F.J., Zietman A.L., Fallon M.A., Hayden D.L., Schoenfeld D.A., Kantoff P.W., Finkelstein J.S. Pamidronate to Prevent Bone Loss During Androgen-Deprivation Therapy for Prostate Cancer. N. Engl. J. Med. 2001; 345: 948–955
   PubMed Web of Science ®Google Scholar
• Green J.R., Müller K., Jaeggi K.A. Preclinical Pharmacology of CGP 42'446, a New, Potent, Heterocyclic Bisphosphonate Compound. J. Bone Miner. Res. 1994; 9: 745–751
   PubMed Web of Science ®Google Scholar
• Bare S., Kimmel D., Binkley N., Schaffer V., Green J. Zoledronate (CGP 42,446) Suppresses Turnover Without Affecting Mineralization in Cancellous Bone of the Ovariectomized Non-human Primate. J. Bone Miner. Res. 1997; 12(suppl 1)S473, Abstract S482
   Google Scholar
• Binkley N., Kimmel D., Bruner J., Haffa A., Davidowitz B., Meng C., Schaffer V., Green J. Zoledronate Prevents the Development of Absolute Osteopenia Following Ovariectomy in Adult Rhesus Monkeys. J. Bone Miner. Res. 1998; 13: 1775–1782
   PubMed Web of Science ®Google Scholar
• Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M., Coleman R.E., Reitsma D.J., Seaman J.J., Chen B.L., Ambros Y. Zoledronic Acid Versus Pamidronate in the Treatment of Skeletal Metastases in Patients with Breast Cancer or Osteolytic Lesions of Multiple Myeloma: A Phase III, Double-Blind, Comparative Trial. Cancer J. 2001; 7: 377–387
   PubMed Web of Science ®Google Scholar